Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17541988 | 0.95 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23234102 | 0.80 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28910371 | 0.74 | TRPV1 (0.71) | NPC1RAB9ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL18862968 | 0.74 | KDM1A (0.40) | — | |
| Trifluoroacetic Acid SCHEMBL18862967 | 0.74 | — | — | |
| SCHEMBL10939703 | 0.72 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL611657 | 0.72 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9767723 | 0.72 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17542065 | 0.72 | SMN1; SMN2 (0.52) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1989485 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186224-B1 | SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS | HOFFMANN LA ROCHE (CH) | 2021-04-21 | — | — | EP | disclosed |
| US-10023559-B2 | Substituted azetidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170144994-A1 | SUBSTITUTED AZETIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023559-B2 | Substituted azetidine derivatives | HTR1B, MTNR1B, DRD2 | NPC1 214/4885RAB9A 210/4885SMN1; SMN2 1381/4885 |
| US-20170144994-A1 | SUBSTITUTED AZETIDINE DERIVATIVES | HTR1B, MTNR1B, DRD2 | NPC1 214/4885RAB9A 210/4885SMN1; SMN2 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.